Eli Lilly has agreed to acquire Orna Therapeutics in a deal valued at up to $2.4 billion, marking a significant expansion of the pharmaceutical giant's RNA therapeutics portfolio. The acquisition represents Lilly's latest strategic move to strengthen its position in the rapidly evolving biotechnology sector, particularly in the area of messenger RNA and circular RNA technologies.

Orna Therapeutics, a clinical-stage biotechnology company, has been developing innovative RNA-based therapies that could address various diseases. The company's proprietary oRNA platform technology has shown promise in creating more stable and effective RNA therapeutics compared to traditional linear mRNA approaches. This acquisition aligns with Lilly's broader strategy to invest in cutting-edge biotechnology platforms that could revolutionize treatment options for patients.

The deal underscores the growing importance of RNA therapeutics in the pharmaceutical industry, with major companies increasingly seeking to acquire promising biotech firms with innovative technologies. For Lilly, this acquisition could provide access to Orna's pipeline of potential treatments and enhance its capabilities in developing next-generation RNA-based medicines. The pharmaceutical industry continues to see consolidation as companies seek to secure competitive advantages in emerging therapeutic areas.